Identification of a novel estrogen-regulated gene, EIG121, induced by hormone replacement therapy and differentially expressed in type I and type II endometrial cancer

Clinical Cancer Research

Volumn 11, Issue 23, 2005, Pages 8258-8264

  Deng, Lei ^a   Broaddus, Russell R ^a   McCampbell, Adrienne ^b   Shipley, Gregory L ^b   Loose, David S ^b   Stancel, George M ^b   Pickar, James H ^c   Davies, Peter J A ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CONJUGATED ESTROGEN; EQUILIN; ESTROGEN; ESTRONE SULFATE; POLYCLONAL ANTIBODY; RNA;

ARTICLE; DNA MICROARRAY; EIG121 GENE; ENDOMETRIUM; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FEMALE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MIXED MULLERIAN TUMOR; POSTMENOPAUSE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; UTERUS CARCINOMA;

ADENOCARCINOMA; CASE-CONTROL STUDIES; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); ESTRONE; EXPRESSED SEQUENCE TAGS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 28544441545     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1189     Document Type: Article

References (31)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7.
3. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995;26:1260-7.
4. Lax SF, Kurman RJ. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Pathol 1997;81:228-32.
5. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 2004;444:213-23.
6. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985;56:403-12.
7. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997;57:3935-40.
8. Gurin CC, Federici MG, Kang L, Boyd J. Causes and consequences of microsatellite instability in endometrial carcinoma. Cancer Res 1999;59:462-6.
9. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000;88:814-24.
10. Santin AD, Bellone S, Gokden M, et al. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res 2002;8:1271-9.
11. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975;293:1164-7.
12. McDonald TW, Annegers JF, O'Fallon WM, Dockerty MB, Malkasian GD, Jr., Kurland LT. Exogenous estrogen and endometrial carcinoma: case-control and incidence study. Am J Obstet Gynecol 1977;127:572-80.
13. Antunes CM, Strolley PD, Rosenshein NB, et al. Endometrial cancer and estrogen use. Report of a large case-control study. N Engl J Med 1979;300:9-13.
14. Purdie DM, Green AC. Epidemiology of endometrial cancer. Best Pract Res Clin Obstet Gynaecol 2001; 15:341-54.
15. Liu X, Yao J, Pisha E, et al. Oxidative DNA damage induced by equine estrogen metabolites: role of estrogen receptor-α. Chem Res Toxicol 2002;15:512-9.
16. Deng L, Shipley GL, Loose-Mitchell DS, et al. Coordinate regulation of the production and signaling of retinoic acid by estrogen in the human endometrium. J Clin Endocrinol Metab 2003;88:2157-63.
17. Thorn MH, Studd JW. Oestrogens and endometrial hyperplasia. Br J Hosp Med 1980;23:506, 508-9, 511-3.
18. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6:93-108.
19. Nielsen SN, Podratz KC, Scheithauer BW, O'Brien PC. Clinicopathologic analysis of uterine malignant mixed mullerian tumors. Gynecol Oncol 1989;34: 372-8.
20. Savouret JF, Bailly A, Misrahi M, et al. Characterization of the hormone responsive element involved in the regulation of the progesterone receptor gene. EMBO J 1991;10:1875-83.
21. Chauchereau A, Savouret JF, Milgrom E. Control of biosynthesis and post-transcriptional modification of the progesterone receptor. Biol Reprod 1992;46: 174-7.
22. Brown AM, Jeltsch JM, Roberts M, Chambon P. Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc Natl Acad Sci U S A 1984; 81:6344-8.
23. Ghabreau L, Roux JP, Niveleau A, et al. Correlation between the DNA global methylation status and progesterone receptor expression in normal endometrium, endometrioid adenocarcinoma and precursors. Virchows Arch 2004;445:129-34.
24. Koshiyama M, Yoshida M, Konishi M, et al. Expression of pS2 protein in endometrial carcinomas: correlation with clinicopathologic features and sex steroid receptor status. Int J Cancer 1997;74:237-44.
25. Matias-Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001;32:569-77.
26. Creasman WT, Kohler MF, Odicino F, Maisonneuve P, Boyle P. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol 2004;95:593-6.
27. Alektiar KM, McKee A, Lin O, et al. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO grade 3 cancer? Int J Radiat Oncol Biol Phys 2002;54:79-85.
28. Halperin R, Zehavi S, Langer R, Hadas E, Bukovsky I, Schneider D. Uterine papillary serous carcinoma (pure and mixed type) compared with moderately and poorly differentiated endometrioid carcinoma. A clinicopathologic study. Eur J Gynaecol Oncol 2002; 23:300-4.
29. Cirisano FD, Jr., Robboy SJ, Dodge RK, et al. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 2000;77:55-65.
30. Boruta DM II, Gehrig PA, Groben PA, et al. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer 2004;101:2214-21.
31. Risinger JI, Maxwell GL, Chandramouli GV, et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res 2003;63:6-11.